Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys

Sebastian P Fuchs; José M Martinez-Navio; Eva G Rakasz; Guangping Gao; Ronald C Desrosiers

doi:10.1016/j.omtm.2019.11.010

Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys

Mol Ther Methods Clin Dev. 2019 Nov 26:16:94-102. doi: 10.1016/j.omtm.2019.11.010. eCollection 2020 Mar 13.

Authors

Sebastian P Fuchs¹, José M Martinez-Navio¹, Eva G Rakasz², Guangping Gao³, Ronald C Desrosiers¹

Affiliations

¹ Department of Pathology & Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
² Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53715, USA.
³ Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Abstract

A number of publications have described the use of adeno-associated virus (AAV) for the delivery of anti-HIV and anti-simian immunodeficiency virus (SIV) monoclonal antibodies (mAbs) to rhesus monkeys. Anti-drug antibodies (ADAs) have been frequently observed, and long-term AAV-mediated delivery has been inconsistent. Here, we investigated different AAV vector strategies and delivery schemes to rhesus monkeys using the rhesus monkey mAb 4L6. We compared 4L6 immunoglobulin G1 (IgG1) delivery using the AAV1 versus the AAV8 serotype with a cytomegalovirus (CMV) promoter and the use of a muscle-specific versus a liver-specific promoter. Long-term expression levels of 4L6 IgG1 following AAV8-mediated gene transfer were comparable to those following AAV1-mediated gene transfer. AAV1-mediated gene transfer, using a muscle-specific promoter, showed robust ADAs and transiently low 4L6 IgG1 levels that ultimately declined to below detectable levels. Intravenous AAV8-mediated gene transfer, using a liver-specific promoter, also resulted in low levels of delivered 4L6 IgG1, but those low levels were maintained in the absence of any detectable ADAs. Booster injections using AAV1-CMV allowed for increased 4L6 IgG1 serum levels in animals that were primed with AAV8 but not with AAV1. Our results suggest that liver-directed expression may help to limit ADAs and that re-administration of AAV of a different serotype can result in successful long-term delivery of an immunogenic antibody.

Keywords: AAV vector; AAV-antibody delivery; AAV1; AAV8; CMV promoter; Desmin promoter; TBG promoter; anti-drug antibody responses; monoclonal antibody; prime-boost immunization.

Abstract

Grants and funding